Welcome to our dedicated page for Lantheus Holding news (Ticker: LNTH), a resource for investors and traders seeking the latest updates and insights on Lantheus Holding stock.
Lantheus Holdings, Inc. reports news on its radiopharmaceutical business, including diagnostic imaging agents, radiotherapeutic assets, regulatory decisions and financial results. The company organizes revenue around Radiopharmaceutical Oncology, Precision Diagnostics and Strategic Partnerships and Other Revenue, with products used by hospitals, independent imaging centers, government facilities and distribution partners in the United States and abroad.
Recurring updates include quarterly earnings, business guidance, FDA activity for products such as PYLARIFY TruVu, PYLARIFY, Lutetium Lu 177 Dotatate (PNT2003) and LNTH-2501, share repurchases, investor presentations and strategic updates involving radiodiagnostics and radiotherapeutic programs.
Lantheus Holdings, Inc. (NASDAQ: LNTH) is set to host a conference call on November 5, 2020, at 8:00 a.m. ET to discuss its Q3 2020 financial and operating results. Interested parties can join the call by dialing 1-866-498-8390 (U.S.) or 1-678-509-7599 (international), using passcode 8872902. A live webcast will also be available on the company's website, with a replay accessible after the call for 30 days. Lantheus is recognized for its innovative diagnostic and therapeutic products, including DEFINITY and TechneLite.
Lantheus Holdings, Inc. (NASDAQ: LNTH) announced that two abstracts featuring its prostate specific membrane antigen artificial intelligence (PSMA AI) tool will be presented at the upcoming European Association of Nuclear Medicine (EANM) Virtual Congress from October 22-30, 2020. The presentations include an oral presentation on the detection and quantification of 18FDCFPyL PET/CT and an e-poster presentation on deep-learning based bladder segmentation using the same imaging technology. These advancements showcase Lantheus's commitment to innovation in diagnostic imaging.
Lantheus Holdings (NASDAQ: LNTH) has submitted a New Drug Application (NDA) for PyL™, a PET imaging agent for prostate cancer, to the FDA, requesting Priority Review. If granted, this could reduce the review time from 10 months to 6 months. The NDA is backed by data from two pivotal studies (OSPREY and CONDOR), demonstrating PyL's effectiveness in prostate cancer diagnosis. With about 3.2 million men in the U.S. living with prostate cancer, the successful approval and launch of PyL could significantly impact patient management and treatment outcomes.